J&J
Top Ten most popular articles on Pharmafile.com this week
January 26, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abcam, Alzheimer's, Dr Reddy's, GSK, J&J, JJ, Reckitt Benckiser, Remicade, Sanofi, influenza, opioid crisis, opioids, top ten, valproate
As we come to the end of January, it’s Friday again – time for another rundown of the top ten …
US court upholds ruling that J&J’s Remicade patent is invalid
January 24, 2018Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Remicade, biosimilars, infliximab, patent, pharma
The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis …
J&J withdraws controversial vaginal mesh from Australian market
January 23, 2018Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, lawsuit, pharma, vaginal mesh
Johnson & Johnson has withdrawn its controversial vaginal mesh product from the Australian market after missing a deadline requiring all …
NICE meets Janssen halfway over Darzalex
January 18, 2018Medical Communications, Sales and Marketing J&J, JJ, Janssen, biotech, darzalex, drugs, pharma, pharmaceutical
NICE rejected Janssen’s Darzalex (Daratumumab) back in March last year, concluding that it wasn’t able to accurately determine the efficacy …
Top Ten most popular articles on Pharmafile.com this week
January 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, HIV, J&J, JJ, Johnson & Johnson, Pfizer, Shire, Teva, Xarelto, patient reported outcomes
The Xmas break is now a distant memory as we move further into January, and with another Friday comes another …
Bayer and J&J successfully reverse $28 million Xarelto court payout
January 10, 2018Research and Development, Sales and Marketing Bayer, J&J, JJ, Johnson & Johnson, Xarelto, pharma
Bayer and Johnson & Johnson have managed to avert a payout of $27.8 million after a Pennsylvania state court judge …
Top Ten most popular articles on Pharmafile.com this week
January 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, J&J, JJ, NICE, Pfizer, Spark Therapeutics, Valeant, top ten
Happy New Year from Pharmafile.com! We hope the first week of 2018 hasn’t been too rough. To the surprise of …
Pharmafile.com’s top ten stories of 2017
December 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit
After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …
J&J’s Darzalex cuts risk of disease progression and death by 50%, new study shows
December 13, 2017Research and Development Genmab, J&J, JJ, Janssen, Johnson & Johnson, darzalex, multiple myeloma, pharma
Johnson and Johnson has revealed data which demonstrates that Darzalex (daratumumab), when combined with a regimen of bortezomib, melphalan and …
J&J’s third quarter: The good and the bad
October 18, 2017Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Janssen, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical
It was a mixed bag for Johnson & Johnson on its announcement of third quarter results. It could largely be …
Top Ten most popular articles on Pharmafile.com this week
September 29, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, EMA, FDA, HIV, J&J, JJ, Kevzara, Mylan, NICE, Sanofi, nash, top ten
It’s Friday, and it’s time for another round up of the most popular articles on pharmafile.com over the last seven …
J&J backs out of $1.1 billion hep C deal, wiping 22.2% from Achillion’s stock
September 12, 2017Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, achillion, hepatitis C, pharma
Johnson & Johnson has announced that it is to back out of a $1.1 billion deal with Achillion Pharmaceuticals to …
Has Trump’s power over pharma come to an end after Charlottesville?
August 31, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Donald Trump, J&J, JJ, Kenneth Frazier, MSD, President trump, Trump, life sciences, medicine, pharma, pharmaceuticals, president
In a shock move that was to have deeply resonant consequences, MSD Chairman and Chief Executive Officer Kenneth Frazier announced …
Johnson & Johnson face major lawsuit over vaginal mesh
July 4, 2017Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, lawsuit, vaginal mesh
Johnson & Johnson will face a lawsuit after 700 Australian women launched a class action suit over the failures of …
Actelion spin-off hit by blow shortly before buyout
June 9, 2017Medical Communications, Research and Development Actelion, Idorsia, J&J, JJ
Idorsia, the spin-off R&D company of Actelion, has been hit a blow even before it has left the ground. The …
Latest content
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
